Congenital chylothorax treated with octreotide.
Congenital chylothorax is the accumulation of lymphatic fluid within the pleural space. Cases unresponsive to conservative management usually require surgery. Octreotide has been used successfully to treat post-traumatic chylothoraces in the pediatric and adult population. Its exact mode of action is uncertain but it is believed to reduce lymphatic drainage by a direct action on splanchnic lymph flow. We report a case of congenital chylothorax where surgery was avoided with the compassionate trial of the somatostatin analogue, octreotide. A 33 week gestation female infant, born with the presence of large bilateral pleural effusion, was unresponsive to conservative management. Octreotide was commenced on day 15, with 10 days of an octreotide infusion, initially 0.5 microg/kg per hour and increased daily by 1 microg/kg per hour to 10 microg/kg per hour. Treatment was associated with prompt respiratory improvement prior to cessation of pleural drainage over the 10 day. She remains well at 6 months of age. Further studies are required to ascertain its true value in congenital chylothorax.
Sahin
Yasin
Y
Department of Pediatrics, SSK Region Hospital and Medical Faculty of Gaziantep University, Turkey. pediatristsahin@mynet.com
Aydin
Derya
D
D001034:Apgar Score; D002916:Chylothorax / Q000151:congenital* / Q000188:drug therapy*; D004322:Drainage; D005260:Female; D005500:Follow-Up Studies; D005765:Gastrointestinal Agents / Q000008:administration & dosage / Q000627:therapeutic use; D005865:Gestational Age; D006801:Humans; D007231:Infant, Newborn; D015282:Octreotide / Q000008:administration & dosage / Q000627:therapeutic use*; D010996:Pleural Effusion / Q000151:congenital / Q000601:surgery; D012121:Respiration, Artificial; D013997:Time Factors; D016896:Treatment Outcome
D005765:Gastrointestinal Agents; D015282:Octreotide